South East Asia IVD Market (2025-2032)
The South East Asia IVD Market is expected to record a CAGR of 7% from 2025 to 2032, reaching $4.11 billion by 2032.
- Published
- Jan 2025
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MR-930
- Base year
- 2024
- 2032 · FORECAST
- $4.11B
- 2032
- $4.11B
- CAGR 2025–2032
- 7%
2024 baseline · 2025–2032 forecast at 7% CAGR · hover a bar for the value
Key highlights
In 2025, the Molecular Diagnostics Segment is Expected to Grow at the Highest CAGR During the Forecast Period
The Reagent, Assays, and Kits Segment is Projected to Register the Highest CAGR During the Forecast Period
The Cardiology Segment is Projected to Register the Fastest Growth During the Forecast Period
Point of Care Testing Segment is Expected to Grow at the Highest CAGR During the Forecast Period
Indonesia To Dominate the Regional Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 4.11 billion |
| CAGR (2025–2032) | 7% |
| Format | PDF, Excel & Cloud Portal · 200 pages |
| Segments Covered | By Offering: Kits, Software · By Technology: Immunoassay, Molecular Diagnostics, Rapid Tests, Biochemistry · By Application: Infectious Diseases, Oncology, Diabetes · By Diagnostic Approach: Lab, POC |
| Key Companies | Abbott Laboratories (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd., PerkinElmer, Inc. (U.S.), QIAGEN N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc. (U.S.), Sysmex Corporation. (U.S.) |
Report overview
Segments covered: offering, technology, application, diagnostic approach.
In vitro diagnostics (IVD) are tests performed on biological samples such as blood, saliva, and other tissues taken from the human body to detect a wide range of diseases. IVD tests screen biological samples to monitor individuals’ health and prevent or diagnose diseases. These consist of various tests based on techniques such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, polymerase chain reaction (PCR), isothermal nucleic acid amplification, and next-generation sequencing. These tests can be performed in laboratories, homes, and healthcare facilities.
The growth of this market is driven by the high prevalence of infectious diseases and the rising risk of emerging infections, the high burden of chronic diseases, and the growing focus on strengthening the healthcare industry in the region. Additionally, growing awareness regarding early disease diagnosis and growing medical tourism in the region are expected to create growth opportunities for the stakeholders in this market. However, the large import of tests and instruments and limited local manufacturing facilities restrain the growth of this market. Poor healthcare access in remote populations is a major challenge to market growth.
The factors propelling the segment's growth include the high burden and increasing prevalence of cardiac disorders in the region, growing research on the development of cardiac biomarkers, and initiatives taken by organizations to increase awareness regarding cardiac diseases.
The rate of deaths due to non-communicable diseases in South East Asia is high.
According to the World Heart Federation, cardiovascular diseases account for around one-third of the total deaths in South East Asia, accounting for 4 million deaths per year.
(Note: Other end users include long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories.)
Report infographic
South East Asia IVD Market Assessment, by Diagnostic Approach
- Lab Testing
- OTC/Self-testing
- Point-of-care Testing
Market dynamics
1 factors across 1 forceFocus on Strengthening of Healthcare Infrastructure a Major Factor for Market Growth
Development of healthcare infrastructure leads to increased accessibility of healthcare institutions, disease diagnostics & management, and improved overall health system. Compared to other developed regions, the healthcare system is underdeveloped in South East Asia. Looking at the high burden of infectious and chronic diseases in the region, governments and international organizations are focusing on developing healthcare in the region. For instance, in 2021, the U.S. government provided USD 40 million to the Association of Southeast Nations to strengthen the region's research and health system capacity.
Moreover, in 2021, the World Health Organization launched the ‘South-East Asia Regional Strategy for Primary Health Care: 2022-2032’ initiative. This initiative aims to accelerate the progress of all the countries in the South East Asia region towards universal health coverage (UHC) and health security and health-related sustainable development goals. Such initiatives are expected to strengthen the healthcare systems of the countries in the region, leading to increasing demand for in vitro diagnostic testing and ultimately driving market growth.
Table of contents
13 chapters · 108 sections · 200 pages · click to expandSegmental analysis
By Technology
- The Molecular Diagnostics Segment is Expected to Grow at the Highest CAGR During the Forecast Period
- The segment's growth can be attributed to the initiatives by the government, private players, and institutions to support the development of molecular diagnostics and constant innovation and advancements in molecular technologies.
- Molecular Diagnostics
- Point-of-Care (PoC) Diagnostics Lateral Flow Assays/Rapid Tests
- Radioimmunoassay
By Offering
- The Reagent, Assays, and Kits Segment is Projected to Register the Highest CAGR During the Forecast Period
- The rising adoption of point-of-care tests, the rising prevalence of chronic & infectious diseases, and the increasing launches of new disease-specific kits are the key factors contributing to the growing demand for consumables.
- Furthermore, the COVID-19 pandemic significantly boosted the demand for IVD reagents, assays, and kits in the region.
- For instance, in June 2020, WHO, in collaboration with the Indonesian Ministry of Health to enhance COVID-19 case detection and help strengthen Indonesia’s laboratories, supported the procurement and distribution of COVID-19 test kits.
- Reagents & Kits
- Software & Services
By Application
- Point of Care Testing Segment is Expected to Grow at the Highest CAGR During the Forecast Period
- The increasing demand for rapid and accurate testing is due to the large number of deaths caused by non-communicable diseases, including cardiovascular diseases, cancer, and diabetes, among others.
- Furthermore, the initiatives for strengthening healthcare infrastructure in the regions drive segment growth.
- The increasing demand for rapid and accurate testing is due to the large number of deaths caused by non-communicable diseases, including cardiovascular diseases, cancer, and diabetes, among others.
- Furthermore, the initiatives for strengthening healthcare infrastructure in the regions drive segment growth.
- The large share of the segment can be attributed to the majority and complex diagnostic tests carried out by diagnostic laboratories, the high burden of infectious and chronic diseases, and the associations of hospitals with diagnostic laboratories.
- Hospitals are people's primary choice if symptoms are onset for any disease or disorder.
- Most regional hospitals outsource the test samples to diagnostic laboratories for precise test results.
- Infectious Diseases Influenza
Geographic analysis
Asia-Pacific
Largest shareIn 2025, Indonesia is expected to dominate the South East Asia IVD market. The factors attributed to the large share are the high prevalence of infectious diseases, the increasing prevalence of chronic diseases, and the growing awareness regarding early disease diagnosis. For instance, new caser cases are estimated to increase to 645,436 by 2040 from 396,914 cases in 2020 (Source: GLOBCAN). Indonesia To Dominate the Regional Market Vietnam Thailand Singapore Philippines Malaysia Rest of South East Asia
Competitive landscape
- Abbott Laboratories (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche Ltd. · Switzerland
- PerkinElmer, Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Siemens Healthineers AG · Germany
- Thermo Fisher Scientific Inc. (U.S.)
- Sysmex Corporation. (U.S.)
Frequently asked questions
The South East Asia IVD market report covers market sizes & forecasts for reagents & kits, systems/instruments, and software & services. The South East Asia IVD market study includes the value analysis of various segments and subsegments of the South East Asia IVD market at the country level.
Cite this report
Meticulous Research. (2025). South East Asia IVD Market - Opportunity Analysis And Industry Forecast (2025-2032) (Report No. MR-930). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/south-east-asia-ivd-market-5613